Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy

Parkinsonism and Related Disorders

Volumn 11, Issue 3, 2005, Pages 151-155

  Mazzella, L ^a,b   Yahr, M D ^d   Marinelli, L ^a,b   Huang, N ^c   Moshier, E ^d   Di Rocco, A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c PARKINSON S INSTITUTE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dyskinesias; L dopa; Motor fluctuations; Parkinson's disease; Risk factors

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 17044376240     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2004.10.002     Document Type: Article

References (28)

1. J. Jankovic l-dopa strengths and weaknesses Neurology 58 2002 S19 S32
2. J.G. Nutt Motor fluctuations and dyskinesias in Parkinson's disease Parkinsonism Relat Disord 8 2001 101 108
3. J.E. Ahlskog, and M.D. Muenter Frequency of l-dopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 2001 448 458
4. C. Marras, and A.E. Lang Measuring motor complications in clinical trial for early Parkinson's disease J Neurol Neurosurg Psychiatry 74 2003 143 146
5. V.S. Kostic, J. Marinkovic, M. Svetel, E. Stefanova, and S. Przedborski The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications Eur J Neurol 9 2002 9 14
6. A. Peppe, J.M. Dambrosia, and T.N. Chase Risk factors for motor response complications in l-dopa treated parkinsonian patients Adv Neurol 60 1993 698 702
7. A.P. Denny, and M. Behari Motor fluctuations in Parkinson's disease J Neurol Sci 165 1999 18 23
8. F. Grandas, M.L. Galiano, and C. Tabernero Risk factors for l-dopa-induced dyskinesias in Parkinson's disease J Neurol 246 1999 1127 1133
9. H. Baas Dyskinesias in Parkinson's disease. Pathophysiology and clinical risk factors J Neurol 247 S4 2000 12 16
10. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. DeDeyn, C.E. Clarke, and A.E. Lang A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or l-dopa N Engl J Med 342 2000 1484 1491
11. A. Schrag, and N. Quinn Dyskinesias and motor fluctuations in Parkinson's disease; a community-based study Brain 123 2000 2297 2305
12. A.H. Rajput, M.E. Fenton, S. Birdi, R. Macaulay, D. George, B. Rozdilsky, L.C. Ang, A. Senthilselvan, and O. Hornykiewicz Clinical-pathological study of l-dopa complications Mov Disord 17 2002 289 296
13. A. Barbeau Treatment of Parkinson's disease with l-dopa and Ro 4-4602: review and present status Adv Neurol 2 1973 173 198
14. G.C. Cotzias, M.H. Van Woert, and L.M. Schiffer Aromatic amino acids and modification of parkinsonism New Engl J Med 276 1967 374 379
15. M.D. Yahr, R.C. Duvoisin, M.J. Schear, R.E. Barrett, and M.M. Hoehn Treatment of parkinsonism with l-dopa Arch Neurol 21 1969 343 354
16. A. Barbeau, H. Mars, and L. Gillo-Joffroy Adverse clinical side effects of l-dopa therapy F.H. Mc Dowell C.H. Markham Recent advances in Parkinson's disease 1971 FA Davis Co Philadelphia
17. C.H. Markham, L.J. Treciokas, and S.G. Diamond Parkinson's disease and l-dopa. A five-year follow-up and review West J Med 121 1974 188 206
18. N. Quinn, P. Critchley, and C.D. Marsden Young- onset Parkinson's disease Mov Disord 2 1987 73 91
19. G. Gomez Arevalo, R. Jorge, S. Garcia, O. Scipioni, and O. Gershanik Clinical and pharmacological differences in early-versus late-onset Parkinson's disease Mov Disord 12 1997 277 284
20. K.A. Reardon, M. Shiff, and P.A. Kempster Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years Mov Disord 14 1999 605 611
21. M.M. Hoehn Parkinsonism treated with l-dopa: progression and mortality J Neural Trans Suppl 19 1983 253 264
22. A.J. Lees, R. Katzenschlager, J. Head, and Y. Ben-Shlomo Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial Neurology 57 2001 1687 1694
23. P.J. Blanchet The fluctuating parkinsonian patient: clinical and pathophysiological aspects Can J Neurol Sci 30 2003 S19 S26
24. T.N. Chase, M.M. Mouradian, and T.M. Engber Motor response complications and the function of striatal efferent systems Neurology 43 6 1993 S23 S27
25. Parkinson Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa Ann Neurol 39 1996 37 45
26. S. Fahn The spectrum of levodopa-induced dyskinesias Ann Neurol 47 suppl1 2000 S2 S11
27. P.J. Garcia Ruiz, E. Meseguer, J. del Val, A. Vazquez, V. Sanchez Bernardos, and A. Vazquez Motor complications in Parkinson disease: a prospective follow-up study Clin Neuropharmacol 27 2004 49 52
28. F. Calon, M. Dridi, O. Hornykiewicz, P.J. Bedard, and A.H. Rajput Di Paolo T Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127 2004 1075 1084